Affymetrix Inc: (NASD: AFFX)

$3.67

-0.06 (-1.61%)

Volume 353,036

May 22 04:00 PM ET

Zacks Rank: 4-Sell

Zacks Rank	Definition	Annualized Return
#1	Strong Buy	26.6%
#2	Buy	18.71%
#3	Hold	10.12%
#4	Sell	4.32%
#5	Strong Sell	2.16%
S&P	500	9.93%

Overview Quote

            Stock Activity
        
		Day Low - High
		3.66 - 3.86
	
		52wk Low - High
		2.96 - 5.50
	
		Previous Close
		3.73
	
		Avg. Volume
		522,118
	
		Industry
		MED-BIOMED/GENE
	
		Market Cap
		265.03 M
	
		Div - Yield
		0.00 - 0.00
	
		Beta
		2.17
	
		PE (Forward)
		177.62
	
		Current Year Est.
		0.02
	
		Quarterly Earnings ESP 
		0.00%
	
Earnings ESP (Expected Surprise Prediction) is Zacks' proprietary methodology for determining which stocks have the best chance to surprise with their next earnings announcement. The Earnings ESP shows the percentage difference between the Most Accurate Estimate and the Consensus.

                Premium research
            
		Zacks Rank  Short-Term: 1-3 Months
                                                                
                                                                Zacks #1 Rank Strong Buys
                                                                
                                                            This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below. 

                                                                        Zacks Rank
                                                                        Definition
                                                                        Annualized Return
                                                                    
                                                                        #1
                                                                        Strong Buy
                                                                        26.6%
                                                                    
                                                                        #2
                                                                        Buy
                                                                        18.71%
                                                                    
                                                                        #3
                                                                        Hold
                                                                        10.12%
                                                                    
                                                                        #4
                                                                        Sell
                                                                        4.32%
                                                                    
                                                                        #5
                                                                        Strong Sell
                                                                        2.16%
                                                                    
                                                                        S&P
                                                                        500
                                                                        9.93%
                                                                    
Zacks Rank Education - Learn more about the Zacks Rank
Zacks Rank Home - All Zacks Rank resources in one place
Zacks Premium - The only way to get access to the Zacks Rank
                                                        
		4
Sell

		Zacks Recommendation  Long-Term: 6+ Months
                                                                
                                                                All Outperform Rated Stocks
                                                                
                                                            Zacks Recommendations are an excellent predictor of stock price movement over a 6+ month time frame. The recommendations come from the Zacks Equity Research group which combines the Zacks Rank with the insights from their team of over 50 equity analysts. The result is superior long term stock ratings.
The Zacks Recommendations are split into 3 groups: Buy, Hold and Sell. Our Buy recommendations have generated returns of 34.4% in 2006, and 16.69% in 2007. When Zacks Premium members click on the recommendation it will launch them to the Zacks Equity Research report for the stock.    More on these reports below.

                                                                    Difference Between Zacks Rank and Zacks Recommendation

                                                                    Zacks Equity Research Home
Zacks Premium - The only way to get access to Zacks Recommendations
                                                                
		Underperform
	
		Zacks Industry Rank Which industries are set to outperform or underperform the market? You'll find the answer here. We have broken down all industries into over 200 classifications. Then ranked these industries using the most powerful indicator we know (the Zacks Rank). The higher the industry rank, the better the industry should perform in the future. Once you have found an attractive industry then check out the Rank in Industry to find the best stocks within the industry.
When Zacks Premium members click on the Zacks Industry Rank link they will see the full listing of industries and their current rankings.

                                                                About Zacks Industry Rank

                                                                Zacks Industry Rank - All current industry ranks. 

                                                                Zacks Premium - The only way to get access to the Zacks Industry Rank
                                                            
		96 out of 265
	
		Equity Research Report The Zacks Recommendations and Zacks Target Prices are just two of the valuable resources you'll find in the reports created by the Zacks Equity Research group. When Zacks Premium members click on this link they will taken to a page that gives them access to the Zacks Equity Research report for the stock.

                                        Zacks Equity Research Home
                                        Zacks Premium - The only way to get access to Zacks Recommendations
                                    
Updated as of 05/3/2013

		PREMIUM
	
    (  = Change in last 30 days) 
Get all our stock ratings and recommendations with a Free Trial to Zacks Premium Start Free Trial 
Zacks Premium Home | Zacks Rank Stock Education

                Key Earnings Data
            
                            PE (Forward)
                            177.62
                        
                            PEG Ratio
                            17.76
                        
                            Current Year Est.
                            0.02
                        
                            Current Quarter Estimate
                            0.00
                        
                            Most Accurate Estimate
                            0.01
                        
                            Earnings ESP 
                            0.00%
                        
                            Next Earnings Report Date
                            08-06-2013
                        
                            EPS Last Year
                            -0.19
                        
                            Expected Earnings Growth
                            10.00%
                        
Earnings ESP (Expected Surprise Prediction) is Zacks' proprietary methodology for determining which stocks have the best chance to surprise with their next earnings announcement. The Earnings ESP shows the percentage difference between the Most Accurate Estimate and the Consensus.

            Company Description
        
Affymetrix scientists invented the world's first high-density microarray and began selling the first commercial microarray. Since then, Affymetrix GeneChip technology has become the industry standard in molecular biology research. Affymetrix technology is used by the world's top pharmaceutical, diagnostic and biotechnology companies as well as leading academic, government and not-for-profit research institutes. Affymetrix' patented photolithographic manufacturing process provides the most information capacity available today on an array, enabling researchers to use a whole-genome approach to analyzing the relationship between genetics and health.   
Full AFFX Company Report

        
NYSE data is at least 20 minutes delayed.
NASDAQ data is at least 15 minutes delayed.

            Interactive Java Charting | Fundamental Charts
        
            <a href="#"><img id="dart_image_1" src="http://b7d61a7c6b8c307bf531-a92a66b9587e2a0aa805bd4e70b98407.r95.cf2.rackcdn.com/images/zacks/logos/zacks_logo_230x76.png" width="336" height="280" border="0" alt="" /></a>        
Turn Earnings Surprises into quick profits.
 
AFFX Chart  by YCharts

Earnings Estimates

	Current Qtr (06/2013)	Next Qtr (09/2013)	Current Year (12/2013)	Next Year (12/2014)
Average Estimate	0.00	0.01	0.02	0.09
Number of Estimates	8	7	10	9
Low Estimate	-0.02	-0.02	-0.07	0.00
High Estimate	0.06	0.07	0.20	NA
Year Ago EPS	-0.13	-0.03	-0.20	0.02
EPS Growth	103.85%	142.86%	110.50%	333.86%

More AFFX Estimates

Average Earnings Estimates for AFFX

EPS Growth for AFFX

Industry Analysis

Name	Symbol	Previous Close
AFFYMETRIX INC	AFFX	3.73
AETERNA ZENTARS	AEZS	2.08
ANIKA THERAPEUT	ANIK	14.45
GENTIUM SPA-ADR	GENT	8.90
AASTROM BIOSCI	ASTM	0.57
ACADIA PHARMA	ACAD	13.79
ACHILLION PHARM	ACHN	7.75
ADDEX THERA LTD	ADDXF	6.94
AFFYMAX INC	AFFY	1.45
ALEXION PHARMA	ALXN	102.67

Sector:Medical>> Industry:MED-BIOMED/GENE

COMPARE TICKER vs. Its Peers

Zacks Commentary

Affymetrix Reports Disappointing 1Q

May 02, 2013

Affymetrix Down to Underperform

Apr 15, 2013

Affymetrix to Disappoint in 1Q

Apr 10, 2013

Zacks Rank #5 Additions for Tuesday

Apr 09, 2013

Affymetrix Inks Deal with UK Biobank

Mar 28, 2013

Affymetrix Links Up with DNA Link

Feb 11, 2013

Affymetrix's 4Q EPS In Line

Feb 01, 2013

Luminex Wins FDA Clearance

Jan 16, 2013

More AFFX Zacks Commentary

Financials

EPS TTM	-0.19
Sales	296
Net Income	-15
Price/Earnings	NA
Price/Book	1.01
Price/Cash Flow	8.65
Price/Sales	0.86

More AFFX Financials

News

Affymetrix Names Gavin Wood as Executive VP and CFO - Close-Up Media

May 23, 2013

Biochip Products and Services Market - U.S. Industry Analysis, Size, Share, Growth, Trends and Forecast, 2012 - 2018 - M2

May 22, 2013

Affymetrix Appoints Gavin Wood as Executive Vice President and Chief Financial Officer - Businesswire

May 20, 2013

Affymetrix Names Gavin Wood CFO - Benzinga

May 20, 2013

Affymetrix Ranks the Lowest in Terms of Price to Book Ratio in the Life Sciences Tools & Services Industry (AFFX, CBMX, SDIX) - Financial News Network Online - News Corner

May 16, 2013

The Global Proteomics Market to Grow At A CAGR Of 14.43 Percent over the Period 2012-2016 - M2

May 10, 2013

Affymetrix Q1 net loss increases - Datamonitor

May 9, 2013

Affymetrix, Inc.Corporate Event Announcement Notice - Wall Street Horizon

May 1, 2013

See All News Stories on AFFX

Broker Recommendations

Current ABR	3.10
ABR (Last Week)	3.10
# of recs in ABR	10
Average Target Price	4.57
Industry Rank by ABR	96 out of 265
Rank in Industry	135 out of 157

More AFFX Broker Recommendations

Day Low - High	3.66 - 3.86
52wk Low - High	2.96 - 5.50
Previous Close	3.73
Avg. Volume	522,118
Industry	MED-BIOMED/GENE
Market Cap	265.03 M
Div - Yield	0.00 - 0.00
Beta	2.17
PE (Forward)	177.62
Current Year Est.	0.02
Quarterly Earnings ESP	0.00%

PE (Forward)	177.62
PEG Ratio	17.76
Current Year Est.	0.02
Current Quarter Estimate	0.00
Most Accurate Estimate	0.01
Earnings ESP	0.00%
Next Earnings Report Date	08-06-2013
EPS Last Year	-0.19
Expected Earnings Growth	10.00%

Username: Password:

Remember me [?]

Affymetrix Inc: (NASD: AFFX)

$3.67

-0.06 (-1.61%)

Volume 353,036

May 22 04:00 PM ET

Stock Activity

Premium research

Zacks Rank Short-Term: 1-3 Months

Zacks Recommendation Long-Term: 6+ Months

Zacks Industry Rank

Equity Research Report

Key Earnings Data

Company Description